Analysts expect CareDx Inc (NASDAQ:CDNA) to report $-0.22 EPS on May, 5.They anticipate $0.18 EPS change or 45.00% from last quarter’s $-0.4 EPS. After having $-0.15 EPS previously, CareDx Inc’s analysts see 46.67% EPS growth. About 36,130 shares traded. CareDx Inc (NASDAQ:CDNA) has declined 80.60% since September 20, 2016 and is downtrending. It has underperformed by 92.18% the S&P500.
Among 17 analysts covering Perrigo Company Plc (NYSE:PRGO), 5 have Buy rating, 1 Sell and 11 Hold. Therefore 29% are positive. Perrigo Company Plc had 40 analyst reports since October 23, 2015 according to SRatingsIntel. The stock of Perrigo Company plc Ordinary Shares (NYSE:PRGO) has “Buy” rating given on Wednesday, November 18 by B. Riley & Co. The stock of Perrigo Company plc Ordinary Shares (NYSE:PRGO) has “Neutral” rating given on Friday, March 3 by B. Riley & Co. The stock of Perrigo Company plc Ordinary Shares (NYSE:PRGO) earned “Neutral” rating by JP Morgan on Thursday, August 11. The stock of Perrigo Company plc Ordinary Shares (NYSE:PRGO) earned “Hold” rating by Jefferies on Thursday, August 11. The rating was upgraded by Deutsche Bank to “Buy” on Friday, July 22. The firm earned “Buy” rating on Wednesday, February 22 by Canaccord Genuity. The firm has “Neutral” rating by B. Riley & Co given on Friday, November 11. The stock has “Neutral” rating by JP Morgan on Wednesday, November 18. The firm earned “Hold” rating on Tuesday, April 26 by Jefferies. Barclays Capital initiated the stock with “Overweight” rating in Thursday, January 21 report. See Perrigo Company plc Ordinary Shares (NYSE:PRGO) latest ratings:
03/03/2017 Broker: B. Riley & Co Rating: Neutral Old Target: $83.00 New Target: $67.00 Maintain
28/02/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $100 New Target: $97 Maintain
22/02/2017 Broker: Canaccord Genuity Rating: Buy New Target: $100.0 Initiate
23/01/2017 Broker: Jefferies Rating: Hold Old Target: $84.00 New Target: $70.00 Maintain
17/01/2017 Broker: RBC Capital Markets Rating: Sector Perform Old Target: $92 New Target: $85 Maintain
11/11/2016 Broker: B. Riley & Co Rating: Neutral Old Target: $87 New Target: $97 Maintain
11/11/2016 Broker: Bank of America Old Rating: Underperform New Rating: Neutral Upgrade
CareDx, Inc. is a molecular diagnostics company. The company has market cap of $14.60 million. The Firm is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. It currently has negative earnings. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test , is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection.
Investors sentiment decreased to 1.63 in 2016 Q4. Its down 0.08, from 1.71 in 2016Q3. It dived, as 1 investors sold CareDx Inc shares while 7 reduced holdings. 8 funds opened positions while 5 raised stakes. 7.74 million shares or 4.10% less from 8.07 million shares in 2016Q3 were reported. California Pub Employees Retirement Sys reported 0% stake. 51,694 were reported by Gabelli Funds Ltd Llc. Blackrock Fund Advsr owns 0% invested in CareDx Inc (NASDAQ:CDNA) for 22,276 shares. Thompson Davis stated it has 2,000 shares. Ontario Teachers Pension Plan Board holds 0.01% or 212,591 shares. Jpmorgan Chase reported 87,408 shares. Morgan Stanley reported 0% stake. Vanguard Gru Inc reported 0% in CareDx Inc (NASDAQ:CDNA). Blackrock Inv Ltd accumulated 0% or 1,928 shares. 952,464 are owned by Gagnon Advsrs Limited Company. Teton Advsr invested in 10,000 shares or 0% of the stock. Tpg Gp (Sbs) Advsr invested in 174,378 shares. Moreover, Essex Investment Mgmt Ltd has 0.05% invested in CareDx Inc (NASDAQ:CDNA) for 103,902 shares. Deutsche Bancorp Ag reported 141 shares. Savings Bank Of America De accumulated 0% or 63 shares.
Since January 20, 2017, it had 1 buy, and 0 insider sales for $225,103 activity. $225,103 worth of stock was bought by GAGNON NEIL on Friday, January 20.
Among 3 analysts covering CareDx (NASDAQ:CDNA), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. CareDx had 4 analyst reports since September 25, 2015 according to SRatingsIntel. The stock of CareDx Inc (NASDAQ:CDNA) has “Market Perform” rating given on Monday, September 28 by Raymond James. Mizuho maintained the stock with “Buy” rating in Tuesday, June 14 report. Craig Hallum initiated the stock with “Buy” rating in Friday, September 25 report.
